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Abstract  
 Developing a simple, economic, sensitive and rapid isocratic RP- 
HPLC method for determination of meloxicam (MX) in bulk drug, tablet 
formulation and human serum. The retention time observed for meloxicam 
was just 2.35 minutes using C18 column (150 x 3.0 mm, 5 μm) with a mobile 
phase consisting of acetonitrile: 0.2% formic acid (70:30 v/v%) at a flow rate 
of 1 ml/min with UV detector set at 355 nm. Linearity in concentration range 
of 0.05 – 50 µg/ml, with coefficient of determination, R² = 0.9956; slope= 
25464 and intercept= -8872. The limit of detection and the limit of 
quantification were found to be 0.011 and 0.173 μg/ml, respectively. The 
precision and accuracy of method were checked by calculating RSD% and 
relative error E%, which were found to be reasonable. A RSD% (0.06 and 
0.021%) for marketed brand and human serum, respectively and E% (0.64 
and -0.47 %) for marketed brand and human serum, respectively. The 
method was found to be applicable for the analysis of MX in bulk, tablet 
formulation and human serum. 
 
Keywords: Meloxicam, Isocratic RP-HPLC, Human serum, tablet 
formulation 
 
Introduction 
        Meloxicam, 4- hydroxy-2- methyl-N- (5- methyl- 2- thiazolyl)- 2H- 1, 
2- benzothiazine-3- carboxamide- 1, 1-dioxide (Figure 1) commonly 
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prescribed as non-steroidal anti-inflammatory drug with analgesic and 
antipyretic properties. Prostaglandins are substances that contribute to 
inflammation of joints; it is very efficient for the treatment of rheumatoid 
arthritis, osteoarthritis, and other joint diseases1-3.   
 
Figure 1. Structure of meloxicam 
 
 Literature survey indicated that there are several methods reported for 
the determination of MX in pharmaceuticals like, UV-spectrophotometry 4, 5, 
capillary electrophoresis 6, pulse polarography 7, turbidimetry 8, FI-
chemiluminescence 9 and voltammetry 10. HPLC is the most commonly used 
method for analysis of MX in pharmaceutical dosage forms as well as in 
biological fluids; some of them make use of buffer in the mobile phase and 
they are cumbersome, they required more time for the analysis and also 
expensive 11-14. There are some papers in the literature reporting HPLC 
determination of meloxicam in plasma or serum. All the methods used apply 
extraction procedures15-17. The present study, reports development of an 
accurate, simple, precise, rapid and economical HPLC method with UV 
detection for the quantification of MX in tablet formulation and in human 
serum. 
 
Experimental Section 
Materials and solvents 
      Meloxicam (99% purity) was provided by Awamedica Company for 
Drug Industries and Medical Applications: Awa, Erbil, Iraq. All chemicals 
used were of analytical grade reagents and deionized water was used 
throughout. Acetonitrile (HPLC-grade) was purchased from (Hayman, 
England). Formic acid (analytical grade) was from (BDH, England). 
 
Instruments 
 The HPLC system (Perkin Elemer series 200, USA ) consisted of a 
(Perkin Elemer series 200 LC) pump with a high-pressure range 6000 psi; a 
(Perkin Elemer series 200) UV/VIS LC detector; a C18 column (Perkin 
Elemer series 200, USA) (150 mm×3.0 mm, 5 μm) were used. aAuto 
sampler type (Perkin Elemer series 200, USA) and a (Perkin Elemer series 
200, USA) vacuum degasser were used. Data integration was done using a 
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(Sync Master 793MG, Samsung) software connected with (HP Laser Jet 
1018, China) printer. Detection wavelength was set at 355 nm. Other 
equipment used in this study (Cecil CE3021, UV-VIS spectrophotometer, 
England) was used for spectral measurement with matched 1 cm quartz cell. 
A pH-meter type (HI 931401, Korea) was used for pH reading and electronic 
balance type (Sartorius AG Gottingen B2- 2105 Germany). A centrifuge 
(Jouan Quality System, France) B4i (30002303) was used for blood sample. 
 
Standards and working standards 
 A stock solution, 100 μg/ml of MX was prepared by dissolving 10 mg 
in 100 ml methanol 18, and working standard solutions were prepared by 
suitable dilution of the stock solution with methanol. 
 
Preparation of formulation sample solution 
 Ten tablets each containing 7.5 mg of MX purchased from (local 
pharmacy, Erbil, Iraq), were accurately weighed individually and finely 
powdered. Powdered sample containing 10.0 mg MX was weighed and 
dissolved in methanol. The solution was filtered and the clear solution was 
transferred to a 100 ml volumetric flask. This solution was diluted with 
mobile phase to yield concentrations in the range of working standard 
solution and the solutions were filtered through a 0.45 μm membrane then 10 
µl of these solutions were injected into the HPLC system to analyze the MX 
content by the proposed procedure. 
 
Preparation of serum sample solution 
 1.0 ml of human serum was added into 10 ml of acetonitrile. The 
mixture was vortexed for 1 min and then centrifuged for 15 min at 3500 rpm. 
The obtained supernatant was filtered by a 0.45-µm membrane18. The clear 
serum solution obtained was spiked with drug solutions to produce desired 
concentration of MX in human serum. The solution was filtered through a 
0.45 μm membrane then 10 µl of this solution was injected into the HPLC 
system. 
 
Chromatographic conditions 
 The mobile phase consisted of acetonitrile: 0.2% formic acid (70:30 
v/v %) with pH of 3.5. The mobile phase was always freshly prepared and 
filtered through a 0.45 μm membrane filter. Chromatography was performed 
at ambient temperature by pumping the mobile phase at a flow rate of 1.0 ml/ 
min and with 10 μl of sample injection. The UV detector was monitored at a 
wavelength of 355 nm. 
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Results and discussion 
HPLC method development and optimization. 
 Several trials were performed to optimize the chromatographic 
conditions for developing a sensitive, precise and accurate RP‐HPLC method 
for the analysis of meloxicam in bulk drug, pharmaceutical dosage form and 
human serum. The UV absorption spectrum of meloxicam was observed 
maximum at wavelength 355 nm as shown in Figure 2. 
Figure 2. Absorption spectrum of meloxicam (10 µg /ml) against mobile phase. 
①Acetonitrile: 0.2%formic acid ②Acetonitrile: methanol: 0.2% formic acid ③Acetonitrile: 
methanol ④Acetonitrile: methanol: water. 
 
 Initial trial experiments were performed to select a suitable solvent of 
mobile system for determination of MX. The suitability of the mobile phase 
was decided on the basis of the sensitivity of the method, time required for 
the analysis, ease of preparation, and use of readily available cost-effective 
solvents. So, various mobile phase systems tried included: acetonitrile-
methanol-water (40:40:20 v/v/v %), acetonitrile-methanol (50:50 v/v %), 
methanol-0.2%formic acid (50:50 v/v %), acetonitrile-0.2%formic acid 
(50:50 v/v %), acetonitrile-methanol- 0.2% formic acid (40:40:20 v/v/v %). 
A mobile phase system of (acetonitrile: 0.2% formic acid) as it get better 
chromatogram with a clear peak and at the lowest overlap with neighboring 
peaks. Then selection the ratio of the optimum mobile phase compositions 
has been studied. It was found that the best ratio of the mobile phase was 
(70:30 v/v %) from acetonitrile: 0.2% formic acid has got the best clear 
chromatogram and less interference with neighboring peaks. The 
determination of meloxicam was greatly affected by changing the pH values 
in the range of 1.3 to 5.5. The plots of the experimental data of capacity 
factor (Ќ) as a function of pH of the mobile phase (Figure 3) show that the 
maximum value has been at pH value of 3.5 and by increasing pH value, the 
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capacity factor (Ќ) has been decreased, therefore the pH value of 3.5 for the 
mobile phase was recommended for the subsequent experiments. 
        
Figure 3.  Effect of pH of the mobile phase. 
 
 Then effect of concentration of formic acid has been tried  by 
different concentrations in the range (0.05-0.3 %) were tested for optimum 
ionization of the analyte and it was found that 0.2% formic acid gave the best 
result (Figure 4).  
 In order to investigate the effect of the flow rate on the retention 
times (tR) of MX, flow rate in the rang (0.5-1.2 ml/ min) were studied. The 
aim of choosing the optimum flow rate was to obtain a short analysis time, 
which in turn prevents solute band brooding; this finally leads to increasing 
column efficiency 19. Figure 5 showed that the retention time of MX 
decreased with increasing the flow rate. A flow rate of 1 ml/min was selected 
to obtain a maximum resolution in a suitable analysis time and in the allowed 
range of capacity factor (Ќ). The optimum working conditions for the 
determination of meloxicam by HPLC isocratic elution systems were 
illustrated in Table 1. 
 
Figure 4. Effect of concentration of formic acid.  Figure 5. Effect of flow rate of the mobile 
phase. 
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Table 1.  The optimum working conditions for the determination of meloxicam by HPLC 
isocratic elution systems. 
Parameters Value 
Mobile phase Acetonitrile: 0.2% formic acid (70:30 v/v %) 
Sample injection volume 10 µl 
pH 3.5 
Concentration of formic acid 0.2% 
Flow rate 1.0 ml/min 
Column temperature 22°C 
λ maximum 355 nm 
Retention time 2.35 min 
 
Linearity of calibration curves 
 Under optimum conditions illustrated in Table 1, a calibration curve 
was plotted to construct a standard curve for MX between peak areas versus 
drug concentration. The calibration plot showed good linear relationship with 
coefficient of determination, R²= 0.9956; slope= 25464 and intercept= -
8872.2 over the concentration range studied. The range of linearity was 0.05-
50 μg/ml. The linear regression data for the calibration plot was indicative of 
a good linear relationship between peak area and concentration over a wide 
range (Figure 6). 
 
Figure 6. Calibration curve of meloxicam. 
 
Limit of detection (LOD) and limit of quantification(LOQ ) 
 Based on the standard deviation of the response and the slope, LOD 
and LOQ were estimated according to the International Union of Pure and 
Applied Chemistry 20 using the formulae: 
                                            LOD= 3.0 σ/S 
                                             LOQ = 10 σ/S 
 Where σ = the standard deviation of the response for the lowest 
concentration in the range,   S = the slope of the calibration curve. 
 LOD and LOQ were determined from the standard deviations of the 
responses for six replicate determinations. The limit of detection and limit of 
quantification were found to be 0.011 and 0.173 μg/ml, respectively. This 
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indicated the method can be used for detection and quantification of MX 
over a very wide range of concentrations. 
 
Accuracy and precision 
 To check the accuracy and precision of the proposed method was 
evaluated by replicate analysis (n =5) of calibration standards at three 
concentration levels as low, medium and high (4, 14 and 30 µg/ml) were set 
as the control points of the proposed  HPLC method. Precision and accuracy 
were based on the calculated relative standard deviation (RSD %) and 
relative error (E %) of the found concentration compared to the theoretical 
one, respectively. The results illustrated in Table 2 indicated that the method 
was satisfactory.  
Table 2. Accuracy and precision for determination of meloxicam in serum and marketed 
brand. 
Human serum (Sample 1) Marketed brand (Mobic) 
Concentratio
n taken 
(µg/ml) 
Concentratio
n found 
(µg/ml) 
Accurac
y (E %) 
Precisio
n (RSD 
%) 
Concentratio
n found 
(µg/ml) 
Accurac
y (E %) 
Precisio
n (RSD 
%) 
4.0 3.96 -1.0 0.011 4.07 +1.75 0.025 
14.0 13.89 -0.79 0.016 13.90 -0.71 0.071 
30.0 30.12 +0.4 0.036 30.26 +0.86 0.083 
Average -0.47 0.021  0.64 0.06 
*Average of five determinations. 
 
Table 3. Optical, regression characteristics of the proposed HPLC method for assay 
meloxicam. 
Parameters Value 
Linearity range (µg/ml) 0.05-50 
Coefficient of determination, R² 0.9956 
Slope 25464 
Intercept -8872.2 
Limit of detection, LOD( µg/ml) 0.011 
Limit of quantification, LOQ( μg/ml) 0.173 
Relative standard deviation, % 
Marketed brand 
Human serum 
 
0.06 
0.021 
Relative error, % 
Marketed brand 
Human serum 
 
0.64 
-0.47 
  
Application 
 The proposed RP-HPLC system with the optimum conditions 
illustrated in Table 3 were used to determine meloxicam in human serum and 
tablet  formulations by injecting 10 μl of human serum spiked with working 
solution of MX and solutions of formulations.  The results obtained were 
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shown in Table 4. Also the chromatograms of serum sample and marketed 
brands were shown in Figure 7 and 8, respectively. 
Table 4.  Determination of meloxicam in marketed brands and human serum. 
Samples Drug/Brands Sample 
peak area 
(µV.s  ) 
Stated  Amount 
found  
% Assay* ± 
SD 
Marketed 
brands 
Awamedica-  
Meloxicam Awa, 
Iraq.  
391239.74 7.5(mg) 7.43(mg) 99.10± 
0.047 
Boehringer 
Ingelheim-Mobic, 
Germany 
388267.66 7.5(mg) 7.46(mg) 99.47± 
0.012 
 
Serum 
 
Sample 1 
 
 
453062.65 
690265.28 
Spiked with 
MX  
(4µg) 
(30µg) 
 
3.96 µg 
30.12 µg 
 
99.0±0.011 
100.4±0.036 
 
Sample 2 
 
98033.45 
435101.65 
Spiked with 
MX (4µg) 
(30µg) 
 
3.88 µg 
29.56 µg 
 
97.0±0.022 
98.53±0.017 
*Average of five determinations. 
     
Chromatogram of blank treated serum sample (1).        Blank serum 
sample (1) spiked with (30.0 µg/ml) MX.                 
     
 Chromatogram of blank treated serum sample (2).          Blank serum 
sample (2) spiked with (30.0 µg/ml) MX. 
Figure 7.  Chromatograms of serum sample. 
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Chromatogram of Mobic tablet                                Chromatogram       of Meloxicam Awa tablet.  
Figure 8.  Chromatograms of marketed brands. 
 
Comparison of the proposed method. 
 A comparison of the analytical performances of the previously 
reported methods and the proposed method for the determination of MX was 
summarized in Table 5. Compared with previous methods, the proposed 
method has relatively wide concentration range between 0.05-50 (µg/ml) and 
flow rate of the mobile phase as good as those methods previously reported. 
Also the present method didn’t need controlling of temperature; it was done 
in the ambient temperature. The present method has a short retention time 
(2.35 min) compared with the two previous methods that have a long 
retention time (10.2 and 13.83 min), so this is meaning determined a large 
number of samples in a short time.  
Table 5. Comparison between the proposed method and literature methods for determination 
of meloxicam by HPLC. 
Literature method(14) Literature method(17) Present method Analytical 
parameters 
C18 (Spherisorb ODS) 
(250 x 4.6 mm) 
C18 (YMC Pack Pro) C18 (Perkin Elemer series 200) 
(150 x 3.0 mm,5 μm) 
Column type 
Methanol: acetate 
buffer, 
pH 4.3 
45:55(v/v) 
Methanol:phosphate buffer, 
pH 6.0 
40:60(v/v) 
Acetonitrile: 0.2% 
formic acid (70:30 v/v) 
Mobile phase 
Diode array detector, 
365 
Uv-visible, 360 Uv- visible, 355 λ max, nm 
R.T* 50 20 Temperature, 
°C 
1.0 1.0 1.0 Flow rate 
( ml/min) 
13.83 10.2 2.35 Retention time 
(min.) 
20 50 10 Sample 
injection 
volume (µl) 
 
100-/500 
 
0.05-2.5 
 
0.05- 50 
 
Concentration 
range (µg/ml) 
* R.T. is room temperature. 
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Conclusion 
 A simple, precise, accurate, having short chromatographic time, fast, and 
economical RP-HPLC method was developed and validated for the assay of 
meloxicam in serum and tablet formulations. The proposed method showed high 
recoveries with good linearity and precision. It can be concluded that the proposed 
method was a good approach for obtaining reliable results and found to be suitable 
for the routine analysis of meloxicam formulations in quality control. 
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